Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Lifeward Ltd. (LFWD)
USD7.91
-0.09 (-1.13%)
IL NASDAQ Healthcare Medical - Devices
Address
3 Hatnufa Street 2069203
Yokneam Illit, IL
Yokneam Illit, IL
CEO
William Mark Grant
Website
golifeward.com
IPO
2014-09-12
CIK 1607962 ISIN IL0011331076
Also trades on
NASDAQ Capital Market · LFWD (USD)
NASDAQ Capital Market · RWLK (USD)
Description
Lifeward Ltd. is a healthcare technology company specializing in the creation, development, and commercialization of wearable robotic exoskeletons. These sophisticated devices are engineered to restore lower limb mobility for individuals living with spinal cord injuries (SCI), granting them the ability to stand, walk, pivot, and navigate staircases by providing assistive hip and knee motion. Key offerings from the company include the ReWalk Exo-Suit and the ReWalk Personal 6.0. Founded by Amit Goffer on June 20, 2001, the enterprise maintains its corporate headquarters in Marlborough, Massachusetts.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD7.91
-0.09 (-1.13%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
8.8K
Beta
0.37
Float Shares
1.48M
Free Float %
96.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.59% | +5.51% | -1.33% | +5.85% | -6.16% | -3.18% | -56.72% | -86.89% | -95.39% | -99.97% | -99.99% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (5 ratings, all time)
Buy
Price Targets & DCF
Current price
7.91
Low
102.00
+1,189.5%
Consensus
129.00
+1,530.8%
Median
129.00
+1,530.8%
High
156.00
+1,872.2%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 2 |
129.00
+1,530.8%
|
Quality scores
Altman Z-Score
-0.82
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Devices: +11.2%-14.1% Q1'26: -22.1% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+57.1% ★ Q1'26: -21.4% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%-77.7% Q1'26: -93.7% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%-76.7% Q1'26: -263.5% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%-215.9% Q1'26: -1,122.9% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+1,503.0% Q1'26: +84.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-0.10× Q1'26: -0.21× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
3.81M
est.
|
5.87M
est: 6.40M (-8.3%)
|
7.75M
est: 7.99M (-2.9%)
|
6.55M
est: 8.50M (-23.0%)
|
4.87M
est: 6.00M (-18.8%)
|
4.39M
est: 4.68M (-6.1%)
|
5.97M
est: 6.51M (-8.3%)
|
5.51M
est: 5.38M (+2.4%)
|
13.85M
est: 14.20M (-2.4%)
|
25.66M
est: 25.61M (+0.2%)
|
22.03M
est: 24.98M (-11.8%)
|
29.53M
27.60M – 31.46M
+18.2% YoY
|
52.03M
48.64M – 55.43M
+76.2% YoY
|
79.51M
74.33M – 84.70M
+52.8% YoY
|
118.03M
110.33M – 125.72M
+48.4% YoY
|
161.57M
151.03M – 172.11M
+36.9% YoY
|
| EBITDA |
-3.79M
est.
|
-29.79M
est: -6.36M (-368.3%)
|
-21.48M
est: -7.94M (-170.4%)
|
-18.79M
est: -8.45M (-122.3%)
|
-13.72M
est: -5.97M (-130.0%)
|
-11.73M
est: -4.65M (-152.1%)
|
-12.39M
est: -6.47M (-91.4%)
|
-18.90M
est: -5.35M (-253.3%)
|
-21.77M
est: -14.11M (-54.2%)
|
-24.93M
est: -24.19M (-3.1%)
|
-16.56M
est: -23.59M (+29.8%)
|
-27.89M
-29.71M – -26.08M
-18.2% YoY
|
-49.15M
-52.36M – -45.95M
-76.2% YoY
|
-75.11M
-80.01M – -70.21M
-52.8% YoY
|
-111.48M
-118.76M – -104.21M
-48.4% YoY
|
-152.62M
-162.57M – -142.66M
-36.9% YoY
|
| EBIT |
-3.81M
est.
|
-30.52M
est: -6.40M (-377.0%)
|
-22.15M
est: -7.99M (-177.3%)
|
-19.28M
est: -8.50M (-126.8%)
|
-14.05M
est: -6.00M (-134.1%)
|
-12.02M
est: -4.68M (-156.8%)
|
-12.62M
est: -6.51M (-93.8%)
|
-19.08M
est: -5.38M (-254.6%)
|
-23.61M
est: -14.20M (-66.3%)
|
-28.77M
est: -24.41M (-17.9%)
|
-16.89M
est: -23.81M (+29.1%)
|
-28.15M
-29.99M – -26.32M
-18.2% YoY
|
-49.61M
-52.84M – -46.37M
-76.2% YoY
|
-75.80M
-80.75M – -70.86M
-52.8% YoY
|
-112.52M
-119.85M – -105.18M
-48.4% YoY
|
-154.03M
-164.07M – -143.98M
-36.9% YoY
|
| Net Income |
-2.98B
est.
|
-32.50M
est: -3.48B (+99.1%)
|
-24.72M
est: -1.80B (+98.6%)
|
-21.68M
est: -1.02B (+97.9%)
|
-15.55M
est: -154.53M (+89.9%)
|
-12.98M
est: -50.50M (+74.3%)
|
-12.74M
est: -14.60M (+12.8%)
|
-19.57M
est: -18.25M (-7.2%)
|
-22.13M
est: -23.12M (+4.3%)
|
-28.94M
est: -291.52M (+90.1%)
|
-19.91M
est: -123.94M (+83.9%)
|
-33.19M
-36.01M – -30.38M
+73.2% YoY
|
-15.78M
-17.12M – -14.44M
+52.4% YoY
|
-9.17M
-9.95M – -8.39M
+41.9% YoY
|
5.69M
5.20M – 6.17M
+162.0% YoY
|
17.87M
16.36M – 19.39M
+214.3% YoY
|
| SGA |
7.83M
est.
|
22.15M
est: 13.14M (+68.6%)
|
19.05M
est: 16.40M (+16.2%)
|
14.69M
est: 17.46M (-15.9%)
|
11.43M
est: 12.32M (-7.3%)
|
10.73M
est: 9.61M (+11.7%)
|
12.62M
est: 13.37M (-5.6%)
|
16.98M
est: 11.05M (+53.7%)
|
23.92M
est: 29.15M (-18.0%)
|
23.14M
est: 45.20M (-48.8%)
|
22.07M
est: 44.09M (-49.9%)
|
52.12M
48.72M – 55.52M
+18.2% YoY
|
91.84M
85.85M – 97.84M
+76.2% YoY
|
140.35M
131.20M – 149.50M
+52.8% YoY
|
208.32M
194.74M – 221.91M
+48.4% YoY
|
285.18M
266.58M – 303.79M
+36.9% YoY
|
| EPS |
-342.42
est.
|
-5,179.56
est: -400.70 (-1,192.6%)
|
-2,567.76
est: -207.45 (-1,137.8%)
|
-1,236.48
est: -117.25 (-954.6%)
|
-226.80
est: -17.78 (-1,175.6%)
|
-68.88
est: -5.81 (-1,085.5%)
|
-22.32
est: -1.68 (-1,228.6%)
|
-26.40
est: -2.10 (-1,157.1%)
|
-31.08
est: -2.66 (-1,068.4%)
|
-39.96
est: -25.12 (-59.1%)
|
-17.16
est: -10.68 (-60.7%)
|
-2.86
-3.10 – -2.62
+73.2% YoY
|
-1.36
-1.48 – -1.24
+52.4% YoY
|
-0.79
-0.86 – -0.72
+41.9% YoY
|
0.49
0.45 – 0.53
+162.0% YoY
|
1.54
1.41 – 1.67
+214.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-15.72M
OE per share TTM
-12.29
Owner's Yield
-145.66%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
15.7%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
19
Total invested
405.9K
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2025 Q4
Investors holding
19
-2 vs prev Q
New positions
3
Closed positions
4
Increased
12
Reduced
4
Put/Call ratio
0.00
Calls held
29.7K
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | RENAISSANCE TECHNOLOGIES LLC | 129.7K -2.0K (-1.5%) | 74.8K -18.9K (-20.2%) | 0.08% -1.092 pp | 0.00% +0.000 pp | USD2.33 -75.1% | 8 qtrs — |
| 2 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 82.6K -34.2K (-29.3%) | 47.6K -35.5K (-42.7%) | 0.05% -0.989 pp | 0.00% +0.000 pp | USD0.69 -15.9% | 8 qtrs — |
| 3 | TWO SIGMA SECURITIES, LLC | 81.0K +35.4K (+77.4%) | 46.7K +14.2K (+43.8%) | 0.05% -0.356 pp | 0.01% +0.002 pp | USD0.65 -10.8% | 2 qtrs — |
| 4 | JANE STREET GROUP, LLC | 68.6K +29.9K (+77.3%) | 39.6K +12.0K (+43.7%) | 0.04% -0.302 pp | 0.00% +0.000 pp | USD0.65 -10.8% | 2 qtrs — |
| 5 | GSA CAPITAL PARTNERS LLP | 63.8K +63.8K (+100.0%) | 37.0K +37.0K (+100.0%) | 0.04% +0.040 pp | 0.00% +0.003 pp | USD0.58 +0.0% | 1 qtrs NEW |
| 6 | BANK OF AMERICA CORP /DE/ | 63.9K +63.7K (+51,396.8%) | 36.8K +36.7K (+41,696.6%) | 0.04% +0.039 pp | 0.00% +0.000 pp | USD0.58 +0.0% | 8 qtrs — |
| 7 | VIRTU FINANCIAL LLC | 60.5K +37.0K (+158.0%) | 35.0K +18.0K (+105.9%) | 0.04% -0.171 pp | 0.00% +0.000 pp | USD0.63 -7.9% | 2 qtrs — |
| 8 | HRT FINANCIAL LP | 49.1K +29.4K (+149.7%) | 28.0K +15.0K (+115.4%) | 0.03% -0.144 pp | 0.00% +0.000 pp | USD0.61 -4.9% | 3 qtrs — |
| 9 | LPL FINANCIAL LLC | 34.2K +8.0K (+30.3%) | 19.7K +1.0K (+5.5%) | 0.02% -0.213 pp | 0.00% +0.000 pp | USD2.53 -77.1% | 7 qtrs — |
| 10 | XTX TOPCO LTD | 30.4K -10.6K (-25.9%) | 17.6K -11.7K (-39.9%) | 0.02% -0.347 pp | 0.00% -0.001 pp | USD0.71 -18.3% | 2 qtrs — |
| 11 | ROBERTSON STEPHENS WEALTH MANAGEMENT, LLC | 29.7K +29.7K (+100.0%) | 17.1K +17.1K (+100.0%) | 0.02% +0.019 pp | 0.00% +0.000 pp | USD0.58 +0.0% | 1 qtrs NEW |
| 12 | UBS GROUP AG | 19.1K +15.4K (+421.6%) | 11.0K +8.4K (+322.6%) | 0.01% -0.021 pp | 0.00% +0.000 pp | USD0.69 -15.9% | 8 qtrs — |
| 13 | SIMPLEX TRADING, LLC | 4.8K +4.8K (+100.0%) | 2.8K +2.8K (+100.0%) | 0.00% +0.003 pp | 0.00% +0.000 pp | USD0.58 +0.0% | 1 qtrs NEW |
| 14 | MORGAN STANLEY | 2.5K +1.0 (+0.0%) | 1.4K -337.0 (-18.9%) | 0.00% -0.021 pp | 0.00% +0.000 pp | USD2.27 -74.4% | 8 qtrs — |
| 15 | SBI SECURITIES CO., LTD. | 2.3K -77.0 (-3.2%) | 1.3K -364.0 (-21.6%) | 0.00% -0.020 pp | 0.00% +0.000 pp | USD1.39 -58.3% | 5 qtrs — |
| 16 | ADVISOR GROUP HOLDINGS, INC. | 314.00 -1.0K (-76.1%) | 180.00 -663.0 (-78.6%) | 0.00% -0.012 pp | 0.00% +0.000 pp | USD1.82 -68.1% | 8 qtrs — |
| 17 | NATIONAL BANK OF CANADA /FI/ | 142.00 +— (+0.0%) | 82.00 -19.0 (-18.8%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD1.71 -66.1% | 8 qtrs — |
| 18 | WELLS FARGO & COMPANY/MN | 3.00 +— (+0.0%) | 2.00 +— (+0.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.00 -80.7% | 8 qtrs — |
| 19 | HIGHTOWER ADVISORS, LLC | — -1.3K (-100.0%) | — -899.0 (-100.0%) | 0.00% -0.011 pp | 0.00% +0.000 pp | USD— | 8 qtrs SOLD |
| 20 | CITIGROUP INC | — -89.0 (-100.0%) | — -63.0 (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 4 qtrs SOLD |
| 21 | CITADEL ADVISORS LLC | — -214.0K (-100.0%) | — -152.3K (-100.0%) | 0.00% -1.906 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 22 | CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC. | — -84.4K (-100.0%) | — -60.0K (-100.0%) | 0.00% -0.752 pp | 0.00% 0.000 pp | USD— | 3 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - US Core Equity 2 ETF DFAC | 0.00% | 823.86 | 0.17% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
5
Sells
0
Shares acquired
235.6K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+235,603
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-25 | Sigsbee William Mark | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-03-25 | Rozenbaum Moshe H | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-03-25 | Reznick Yehuda | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-03-25 | ORAMED PHARMACEUTICALS INC. | 10% Owner | — | — | Ordinary Shares | 0 | 0.00 | — | 1,250,363 | D | ↗ |
| 2026-03-25 | Kidron Miriam | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-03-25 | KIDRON NADAV | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-03-25 | Grant William Mark | Director / Officer | A-Award | A | Option (Right to Buy) | 172,698 | 6.53 | 1.13M | 172,698 | D | ↗ |
| 2026-03-25 | Adar Almog | Officer | A-Award | A | Option (Right to Buy) | 39,934 | 6.53 | 260.8K | 39,934 | D | ↗ |
| 2025-12-11 | Lynch Jeannine | Officer | A-Award | A | Ordinary Shares, par value NIS 1.75 per share | 50,000 | 0.00 | — | 96,067 | D | ↗ |
| 2025-09-02 | Lynch Jeannine | Officer | S-Sale | D | Ordinary Shares, par value NIS 1.75 per share | 1,591 | 0.64 | 1.0K | 46,067 | I | ↗ |
| 2025-08-13 | Adar Almog | Officer | A-Award | A | Option (Right to Buy) | 225,000 | 0.72 | 161.3K | 225,000 | D | ↗ |
| 2025-08-01 | Turk Joseph E Jr | Director | A-Award | A | Ordinary Shares, par value NIS 1.75 per share | 71,839 | 0.00 | — | 86,457 | I | ↗ |
| 2025-08-01 | Swinford Michael | Director | A-Award | A | Ordinary Shares, par value NIS 1.75 per share | 35,920 | 0.00 | — | 45,960 | I | ↗ |
| 2025-08-01 | Richner Randel | Director | A-Award | A | Ordinary Shares, par value NIS 1.75 per share | 35,920 | 0.00 | — | 57,487 | I | ↗ |
| 2025-08-01 | PODUSKA JOHN WILLIAM SR | Director | A-Award | A | Ordinary Shares, par value NIS 1.75 per share | 35,920 | 0.00 | — | 55,953 | I | ↗ |
| 2025-08-01 | Marshall Robert J. Jr. | Director | A-Award | A | Ordinary Shares, par value NIS 1.75 per share | 35,920 | 0.00 | — | 35,920 | D | ↗ |
| 2025-08-01 | Levy Hadar | Director | A-Award | A | Ordinary Shares, par value NIS 1.75 per share | 35,920 | 0.00 | — | 51,576 | I | ↗ |
| 2025-06-02 | Grant William Mark | Officer | A-Award | A | Option (Right to Buy) | 400,000 | 1.23 | 490.0K | 400,000 | D | ↗ |
| 2025-05-21 | Jasinski Lawrence J | Director / Officer | S-Sale | D | Ordinary Shares, par value NIS 1.75 per share | 1,909 | 1.26 | 2.4K | 98,728 | I | ↗ |
| 2025-01-07 | Lind Global Fund II LP | 10% Owner | S-Sale | D | Ordinary Shares, par value NIS 1.75 per share | 190,734 | 1.94 | 370.0K | 858,696 | I | ↗ |
| 2025-01-06 | Lind Global Fund II LP | 10% Owner | S-Sale | D | Ordinary Shares, par value NIS 1.75 per share | 83,326 | 3.01 | 250.8K | 1,347,780 | I | ↗ |
| 2024-12-13 | Turk Joseph E Jr | Director | P-Purchase | A | Ordinary Shares, par value NIS 1.75 per share | 6,000 | 1.69 | 10.1K | 18,516 | D | ↗ |
| 2024-12-13 | Richner Randel | Director | S-Sale | D | Ordinary Shares, par value NIS 1.75 per share | 4,285 | 1.68 | 7.2K | 0 | I | ↗ |
| 2024-11-25 | Swinford Michael | Director | P-Purchase | A | Ordinary Shares, par value NIS 1.75 per share | 21,622 | 2.03 | 43.9K | 65,040 | D | ↗ |
| 2024-11-22 | Swinford Michael | Director | P-Purchase | A | Ordinary Shares, par value NIS 1.75 per share | 16,907 | 1.83 | 30.9K | 43,418 | D | ↗ |
| 2024-11-20 | Swinford Michael | Director | P-Purchase | A | Ordinary Shares, par value NIS 1.75 per share | 16,471 | 1.84 | 30.2K | 26,511 | D | ↗ |
| 2024-11-02 | Marshall Robert J. Jr. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-09-13 | Jasinski Lawrence J | Director / Officer | S-Sale | D | Ordinary Shares, par value NIS 1.75 per share | 2,672 | 3.26 | 8.7K | 100,637 | — | ↗ |
| 2024-09-03 | Lynch Jeannine | Officer | S-Sale | D | Ordinary Shares, par value NIS 1.75 per share | 1,625 | 3.30 | 5.4K | 47,658 | — | ↗ |
| 2024-08-02 | Lynch Jeannine | Officer | S-Sale | D | Ordinary Shares, par value NIS 1.75 per share | 1,783 | 3.84 | 6.8K | 49,283 | — | ↗ |
| 2024-08-02 | Jasinski Lawrence J | Director / Officer | S-Sale | D | Ordinary Shares, par value NIS 1.75 per share | 2,665 | 3.84 | 10.2K | 103,309 | — | ↗ |
| 2024-07-01 | Lynch Jeannine | Officer | S-Sale | D | Ordinary Shares, par value NIS 1.75 per share | 1,834 | 3.83 | 7.0K | 51,066 | — | ↗ |
| 2024-06-18 | Jasinski Lawrence J | Director / Officer | S-Sale | D | Ordinary Shares, par value NIS 1.75 per share | 3,466 | 4.22 | 14.6K | 105,974 | — | ↗ |
| 2024-05-23 | Turk Joseph E Jr | Director | P-Purchase | A | Ordinary Shares, par value NIS 1.75 per share | 7,916 | 5.01 | 39.7K | 12,516 | — | ↗ |
| 2024-05-23 | Lawless Michael A | Officer | P-Purchase | A | Ordinary Shares, par value NIS 1.75 per share | 2,000 | 4.97 | 9.9K | 4,150 | — | ↗ |
| 2024-05-22 | Turk Joseph E Jr | Director | P-Purchase | A | Ordinary Shares, par value NIS 1.75 per share | 84 | 5.01 | 420.84 | 4,600 | — | ↗ |
| 2024-05-21 | Jasinski Lawrence J | Director / Officer | S-Sale | D | Ordinary Shares, par value NIS 1.75 per share | 1,620 | 4.91 | 8.0K | 109,440 | — | ↗ |
| 2024-04-18 | Swinford Michael | Director | A-Award | A | Ordinary Shares, par value NIS 1.75 per share | 10,040 | 0.00 | — | 10,040 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-211.1K
Shares Outstanding
1.53M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | co-Chief Executive Officer and Director | 442.3K | — | — | — | 31.0K | — | 473.3K | 0.00% | ↗ |
| 2 | 2024 | Chief Sales Officer | 375.0K | — | — | — | — | — | 375.0K | 0.00% | ↗ |
| 3 | 2024 | Vice President of Market Access and Strategy | 359.0K | — | — | — | — | — | 359.0K | 0.00% | ↗ |
| 4 | 2023 | Larry Jasinski, Chief Executive Officer and Director | 442.3K | — | 167.7K | — | 278.7K | — | 888.7K | 18.87% | ↗ |
| 5 | 2023 | Jeannine Lynch, Vice President of Market Access and Strategy | 351.1K | — | 82.5K | — | 113.1K | — | 546.7K | 15.09% | ↗ |
| 6 | 2023 | Michael Lawless, Chief Financial Officer | 316.5K | — | 99.0K | — | 101.9K | — | 517.4K | 19.13% | ↗ |
| 7 | 2022 | Larry Jasinski, Chief Executive Officer and Director | 419.3K | — | 200.0K | — | 234.8K | — | 854.0K | 23.42% | ↗ |
| 8 | 2022 | Jeannine Lynch, Vice President of Market Access and Strategy | 332.8K | — | 137.5K | — | 93.2K | — | 563.5K | 24.40% | ↗ |
| 9 | 2022 | Michael Lawless, Chief Financial Officer | 86.5K | — | 201.4K | — | 23.7K | — | 311.6K | 64.62% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| William Mark Grant | President, Chief Executive Officer & Director | 614.6K | male |
| Jeannine Lynch | Vice President of Market Access & Strategy | 368.0K | female |
| Almog Adar | Chief Financial Officer | 339.1K | male |
| Miri Pariente | Vice President of Operations, Regulatory & Quality | 295.4K | female |
| Craig Peters | Vice President of Sales - North America | — | male |
| Judy Kula | Vice President of Customer Service, Human Resources & Business Affairs | — | female |
ESG Rating
ESG Score History MEDICAL - DEVICES
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for LFWD
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
